Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Preliminary Results
Eckert & Ziegler Publishes Preliminary Figures for Q1/2022 with Deviation in Earnings and Confirms Annual Forecast for 2022
06-Apr-2022 / 19:52 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Berlin, 6 April 2022. Based on preliminary calculations, Eckert & Ziegler AG (ISIN DE0005659700, TecDAX) will achieve sales of around EUR 47 million (previous year: 44) and a net income of around EUR 6.5 million (previous year: 13.8) for the first quarter of 2022. The earnings gap compared to the previous year is explained by a one-off effect of around EUR 6.8 million in the first quarter of 2021, in which the Group divested its tumour irradiation equipment business at a profit.
The forecast for the financial year 2022 published on March 24, 2022 remains unaffected. The Executive Board expects an increase in sales to around EUR 200 million and a net income of around EUR 38 million. The forecast is based on a weighted average exchange rate of USD 1.20 per EUR and is subject to the assumption that no major disruptions continue to result from the developments in Ukraine
The full figures for the first quarter of 2022 will be published on May 12, 2022.
|Company:||Eckert & Ziegler Strahlen- und Medizintechnik AG|
|Phone:||+49 30 941084-138|
|Fax:||+49 30 941084-112|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1322315|
|End of Announcement||DGAP News Service|